Jointly funded research explores cutting-edge RNA sequencing in low-grade serous ovarian cancer4/16/2025 Project Title: Analysis of full-length transcripts in low-grade serous ovarian cancer by long-read sequencing
Research Institute: The University of Texas MD Anderson Cancer Center Principal Investigators: Kwong-Kwok Wong, PhD Award: $115,580 Funded by: STAAR Low-Grade Serous Ovarian Cancer Foundation and Not These Ovaries Two patient-driven ovarian cancer nonprofit — STAAR Low-Grade Serous Ovarian Cancer Foundation and Not These Ovaries — have jointly awarded a $115,580 research grant to investigate new biomarkers that could improve treatment options for patients with low-grade serous ovarian cancer. Conducted by Kwong-Kwok Wong, Ph.D., professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, the laboratory study will use new technology to sequence full-length RNA transcripts in greater detail to identify new gene fusions and biomarkers that could be used to determine whether an LGSOC patient will respond to chemotherapy or endocrine therapy. “This pilot project is exploring a novel technology to perform a more accurate measurement of transcript activities and to discover new genetic markers in LGSOC,” Dr. Wong said. “As the accuracy of long-read sequencing improves, we are optimistic about the potential in clinical applications for patients who need better options.” Only 20% of LGSOC patients respond to platinum-based chemotherapy, the standard of care for other ovarian cancers. Patients typically undergo surgery followed by chemotherapy and treatment with aromatase inhibitors, which block estrogen production. However, outcomes remain limited due to the unique biology of LGSOC and the lack of personalized therapies. This research will analyze RNA samples from patients who responded to either chemotherapy or endocrine therapy—and those who did not—to uncover new molecular patterns that could guide treatment decisions and lead to more tailored, effective care. “This research directly addresses the gap in options for patients with this rare and underfunded cancer,” said Emily Campbell, Executive Director of Not These Ovaries. “We are proud to invest in innovative science that puts patients at the center of progress.” “STAAR was founded to drive critical research for a disease that has been overlooked for too long,” said STAAR Chair Nicole Andrews. “We’re excited to collaborate with Not These Ovaries and MD Anderson to accelerate discoveries that could change lives.” Not These Ovaries is dedicated to quickly funding research and trials to eradicate ovarian cancer, with a focus on understudied and underfunded subtypes that primarily affect younger women. Its transparent model ensures 100% of donations fund immediate research and trials, while also empowering patients and families through education and actionable information. STAAR Low-Grade Serous Ovarian Cancer’s mission is to fund research into potential new treatments for this rare, persistent disease. As the first U.S.-based organization dedicated to LGSOC, we’re working to fill the gap in research funding and drive advancements that will lead to better diagnostic tools, novel therapies, and ultimately, a cure.
0 Comments
Leave a Reply. |
RSS Feed
